Dr. Morris is an Associate Professor in the Department of Gastrointestinal Medical Oncology, where he also serves as the Section Chief for Colorectal Cancer. His clinical practice focuses on the treatment of colorectal and anal cancers, and he has written multiple clinical trials which incorporate novel therapeutic approaches involving targeted therapies and immunotherapy. His research has been supported as a recipient of the ASCO Young investigator Award, NIH/NCI K12 Award, Khalifa Scholar Award, SWOG Hope Foundation Award, NIH/NCI Colorectal Cancer SPORE Early Career Award, Sabin Family Foundation Award, CPRIT Individual Investigator Research Award, and most recently the NIH/NCI R50 Clinical Scientist Award. He is the overall Principal Investigator for the NRG GI005 phase II/III trial evaluating ctDNA as a predictive biomarker for adjuvant chemotherapy in patients with stage II colon cancer and the SWOG S2107 phase II trial for patients with BRAF mutated metastatic colorectal cancer. Institutionally, he is a coleader for the HPV Moonshot and the MD Anderson PI for SWOG on the NCTN LAPS grant.
